ClinicalTrials.gg
TerminatedNCT01821040Updated Oct 24, 2018

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

A Phase 3 interventional study of Lodotra® and Prednisone IR (immediate release) in Polymyalgia Rheumatica, sponsored by Mundipharma Research Limited. Terminated at 1 site in United Kingdom. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-10-24.

Sponsored by Mundipharma Research Limited (part of Mundipharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.

Read the detailed description

The study consists of a screening phase, followed by a 4 week double-blind phase. During the double-blind phase, the patients will be randomised in a 1:1 ratio to either Lodotra® or immediate release prednisone (prednisone IR) plus respective placebo.

After completion of the double-blind phase, patients will be re-randomised in a 1:1 ratio to open-label Lodotra® or prednisone IR for 48 weeks. During the open-label phase, the dose of study medication will be tapered based on titration criteria.

02

Conditions studied

  • Polymyalgia Rheumatica

Browse trials for

Keywords

  • Polymyalgia rheumatica
  • PMR
  • Modified release prednisone
03

In context

Polymyalgia Rheumatica

68 studies on the registry are indexed under Polymyalgia Rheumatica; 22 are open to participants now.

This study's enrollment of 62 is close to the median of 66 across 39 interventional studies indexed under Polymyalgia Rheumatica.

Browse Polymyalgia Rheumatica studies →

Lead sponsor

Mundipharma Research Limited is the lead sponsor of 36 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, 50 years of age or older who provided written .
  2. Females less than one year must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner).
  3. Subjects newly diagnosed with polymyalgia rheumatica and previously untreated with for PMR. The diagnosis of polymyalgia rheumatica must be confirmed by all of the following criteria:

    • New onset bilateral shoulder pain or new onset bilateral shoulder and hip girdle pain.
    • PMR VAS score over the last 24 hours before the Screening Visit ≥ 50 (on a 0 - 100 scale).
    • Morning stiffness duration of ≥ 45 min on the day before the Screening Visit.
    • Acute phase response shown by elevated C-reactive protein (CRP; ≥ 2 times ).
  4. Subjects willing and able to participate in all aspects of the study and comply with the use of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant (positive β-hCG test) or lactating.
  2. Subjects with any /history of to predniso(lo)ne or other ingredients.
  3. Significant renal impairment (serume creatinine > 150 µmol/L).
  4. Significant hepatic impairment (, AST and GGT > 2.5 ).
  5. Subjects suffering from another disease which requires glucocorticosteroid treatment. Topical glucocorticosteroids, e.g. intra-nasal or inhaled glucocorticosteroids are allowed but should be kept at a stable dose throughout the study.
  6. Continued use of systemic within 4 weeks prior to the Screening Visit.
  7. Joint injections with glucocorticoids within 6 weeks prior to the Screening Visit.
  8. Subjects who require treatment with non-permitted concomitant therapies.
  9. Evidence of cardiovascular, renal, hepatic, gastrointestinal or psychiatric disease at the time of screening, as determined by medical history, clinical laboratory tests, results, and physical examination, that would place the subject at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the study results.
  10. Active alcohol or drug abuse.
  11. Subjects suffering from giant cell arteritis, late onset rheumatoid arthritis or other inflammatory rheumatoid diseases.
  12. Subjects suffering from drug-induced myalgia.
  13. Subjects suffering from fibromyalgia
  14. Subjects suffering from systemic lupus erythemathosus.
  15. Subjects suffering from neurological conditions, e.g. Parkinson's disease.
  16. Subjects suffering from active cancer.
  17. Subjects suffering from an active infection.
  18. Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days prior to the Screening Visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Lodotra®

    Lodotra, starting dose of 15mg administered in the evening

    Drug: Lodotra®

  • Active comparator
    Prednisone IR

    Prednisone IR 15mg daily start dose (immediate release) administered in the morning

    Drug: Prednisone IR (immediate release)

Interventions

  • Lodotra, starting dose of 15mg administered in the evening

    Also known as: Modified release prednisone

  • Prednisone IR 15mg daily start dose (immediate release) administered in the morning,

06

What researchers measure

Primary outcomes

  1. To show that treatment with Lodotra® is noninferior to treatment with prednisone IR with regards to the percentage of complete responders.

    Time frame: 4 weeks

Secondary outcomes

  1. Patient reported outcomes

    Time frame: 4 weeks

07

Study locations

1 site
  • Southend University Hospital
    Westcliff on Sea, SS9 9RY, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2013
First posted
Mar 29, 2013
Start
Mar 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Oct 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01821040
Responsible party
Sponsor
First posted
Mar 29, 2013
Start date
Mar 2013
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Oct 24, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion